National Cancer Specimen Handling Guidelines 2020

Objectives

Kenya’s National Specimen Handling Guidelines for Cancer Diagnosis establish a coordinated national framework to improve timely, accurate and equitable cancer diagnosis through standardised specimen collection, handling, processing, referral and pathology reporting. The guidelines support the Kenya Cancer Policy 2019-2030 and implement Pillar 2, Diagnosis, Registration and Surveillance, of the National Cancer Control Strategy 2017-2022.[1]They seek to reduce delayed, incomplete and inaccurate diagnosis, sub-optimal specimen handling, prolonged turnaround times and the advanced-stage presentation that contributes to poorer treatment outcomes.[1][2]

• Standardise the full specimen pathway, from collection and consent through preservation, transport, laboratory processing, reporting, archiving and disposal, for suspected cancer cases.[3][4]
• Institutionalise coordinated specimen-handling and referral systems for priority cancers, enabling timely diagnosis and linkage to care across Kenya’s health sector.[5]
• Improve diagnostic accuracy, pathological staging and treatment planning by prescribing minimum clinical and pathology datasets and using evidence-based reporting protocols.[1][6]
• Support early, accessible, affordable and effective cancer diagnosis, thereby improving treatment outcomes and survival.[3][4]
• Strengthen cancer registration and surveillance through standardised diagnostic information and cancer registries that report incidence and inform prevention and control planning.[2]

The guidelines cover breast, gynaecological, prostate, oesophageal, colorectal and childhood cancers, applying gold-standard pathology reporting and tumour-specific diagnostic procedures where relevant.[7][8]Breast pathways aim to support reliable routine and molecular diagnosis, cancer phenotype identification and individualised treatment.[9][6]Gynaecological pathways support diagnostic confirmation and tumour grading and staging for cervical, endometrial and ovarian cancers.[10][11][12]Childhood cancer provisions prioritise early detection and build capacity for clinical work-up, specimen sampling, referral and specialist investigations because many childhood cancers have high cure potential.[13]

Quality, patient safety, ethical practice, equity and patient autonomy are integral objectives. Patients or guardians should receive information on the reason for testing, specimen collection, expected results process and timelines, costs and any further procedures, and should provide consent before testing.[4]Laboratory practice should protect best interests, safety, fairness, equity and justice while maintaining confidentiality and accurate reporting.[9]

Implementation

Implementation relies on mandatory national standard operating procedures, manuals and forms across all levels of care and among public and private cancer-pathology stakeholders.[4][14]Delivery combines local diagnostic capacity with structured referral to facilities able to provide specialised testing, reporting or consultation.[15][16]National and county governments, the Ministry of Health, National Cancer Control Program, hospitals, laboratories, universities, technical partners and private-sector institutions are identified as contributors to implementation and technical support.[3][17][18]

• Apply standard procedures for patient identification, consent, requisition, sampling, labelling, reception, processing, packaging, transport, storage, archiving, disposal and results reporting.[4]
• Make 10% buffered formalin available at facilities collecting cancer specimens through central processing and distribution to peripheral facilities.[3][5]
• Fix tissue promptly, use suitable containers and preservatives, match specimen labels to requisition forms, and maintain at least two unique identifiers during processing and reporting.[14][19]
• Assign responsibility for specimen handling to hospitals and facilities rather than patients, document all personnel involved in movement and transport, and maintain specimen movement logs.[19]
• Retain feasible processing tasks locally and refer only activities requiring external expertise or equipment, such as specialised microscopy reporting.[19][15]
• Use approved couriers, standard referral documentation, contractual arrangements and sturdy triple packaging with appropriate biohazard, temperature, fragility and orientation labels.[15][16]

Service provision is differentiated by facility level. County referral hospitals are expected to handle fine-needle aspiration or exfoliative cytology, biopsies, resection specimens and bone-marrow aspirates, while national referral hospitals additionally provide molecular testing, immunohistochemistry, genetics and liquid biopsies.[19]Frozen sections are restricted to specialised centres and require cross-consultation in planning and implementation.[19]Referral networks should connect community, primary-care, county-referral and national-referral services, with defined personnel, supplies, information technology, transport and communication arrangements.[16]Universities, teaching hospitals, research institutes, tertiary hospitals and specialised private laboratories may support referral planning and professional consultation.[16]

Laboratories should manage equipment across its lifecycle, including procurement, commissioning, validation, staff induction, maintenance, repair, supplies management and replacement.[20][21]Participating institutions should deploy appropriately trained, registered and licensed personnel and provide orientation, capacity building, competency assessment and continuous improvement for clinicians, pathologists, laboratory staff, transporters, couriers and logistics personnel.[21]Each network laboratory should undertake bio-risk assessment and designate a biosafety officer to coordinate biosafety, biosecurity and safety audits.[21]

Quality management should incorporate internal quality control, external quality assurance, accreditation, inter-laboratory variation monitoring, customer-satisfaction surveys, non-conformance management, root-cause analysis and corrective and preventive action.[14]Quality managers or officers should develop and implement the quality-management system, while laboratories maintain ethical policies, staff training, audit trails and deterrence of fraud or non-compliance.[21][9]Multidisciplinary tumour boards, including tele-tumour boards where appropriate, should support patient management and treatment planning.[21][22]

Monitoring focuses on referral-network performance, specimen traceability, rejection rates, turnaround performance, quality-control and external-assurance results, enabling information technology coverage, and the number and cadre of personnel trained in referral guidelines.[20]Target turnaround times are within seven days for cytology and bone-marrow aspirates and within 14 days for histology, although preliminary histology reports may be issued while ancillary tests are pending.[15]Required retention periods are three months for gross specimens after final reporting, 10 years for paraffin tissue blocks, 20 years for stained slides and indefinite retention for final reports.[15]

The supplied material does not specify a consolidated implementation timetable, national budget, financing mechanism or quantified funding gap. It identifies resource needs including laboratory equipment, commodities, personal protective equipment, trained personnel, information technology, transport, courier services and communication systems.[16][14]

Monitoring & Evaluation

The guidelines establish a laboratory-centred monitoring and accountability approach for cancer specimen handling, diagnostic reporting and referral networks, combining traceability, quality management, performance review and cancer-registration data to improve diagnostic accuracy and timeliness.[2][14][19][20]

• Use cancer registries to maintain cancer-incidence reporting, investigate cancer and its causes, and inform planning and evaluation of prevention and control programmes.[2]
• Track specimens from collection through processing, referral and reporting using unique identifiers, laboratory tracking systems, movement logs and documented handovers.[19][15][16]
• Record referral details including collection site, courier identity, referring laboratory, transit conditions, receipt time, specimen condition, suitability, rejection reasons and the identities or signatures of staff involved in dispatch and receipt.[15][16][17]
• Assess specimens at reception against defined acceptance and rejection criteria, notify requesting clinicians or institutions promptly where deficiencies could result in rejection, and implement corrective processes.[19][15]
• Monitor referral networks routinely, maintain records at every level and use performance data to assess efficiency, effectiveness and emerging operational problems.[20]
• Measure referral-network effectiveness, numbers of specimens sent from satellite sites or to other facilities, specimens fully processed locally, rejection rates, turnaround indicators, internal quality-control and external quality-assurance performance, county information-technology readiness, and personnel trained or oriented in referral guidelines.[20]
• Implement internal quality control, external quality assurance, inter-laboratory variation monitoring, accreditation and customer-satisfaction surveys as components of laboratory quality management.[14]
• Manage non-conformances through identification, root-cause analysis, corrective and preventive action, and assessment of whether corrective actions have been effective.[14][21]
• Maintain records for personnel training and competency assessment, equipment verification, validation and maintenance, and environmental conditions such as temperature and humidity.[14]
• Conduct internal and external audits, safety audits using standard checklists, and accreditation against International Organization for Standardization standards or other recognised national or international standards.[21]
• Assign quality managers or officers responsibility for developing and implementing quality-management systems, and assign a biosafety officer in each network laboratory to coordinate biosafety, biosecurity and safety audits.[21]
• Use ethical controls including laboratory ethics policies, staff training, fraud deterrence, individual analyst log-ins, audit trails, approved methods and defined penalties for non-compliance.[9]

Diagnostic reporting is a core accountability mechanism. Laboratories are expected to use standard operating procedures for reporting and releasing results, including supplementary reports, while clinicians remain responsible for communicating results and counselling patients.[4][15]Synoptic and minimum-data-set reporting is required for several priority cancers, supporting complete documentation of pathological findings, staging and treatment-relevant information.[6][23][24][25][26]

• Achieve turnaround times of up to 7 days for cytology and bone-marrow aspirates and up to 14 days for histology, while allowing preliminary histology reports when ancillary tests remain pending.[15]
• Maintain specimens and records for defined periods: gross specimens for 3 months after the final report, paraffin blocks for 10 years, stained slides for 20 years and final reports indefinitely.[15]
• Document specimen issue to patients and maintain procedures for storage, disposal, research or museum release to support accountability and medico-legal requirements.[15]
• Use forms to capture patient demographics, tumour incidence date, diagnostic basis, primary site, laterality, histology, cytology and morphology, thereby supporting case documentation and cancer data collection.[27]

The guidelines identify late presentation as a major diagnostic concern, noting that approximately 64% of cancer patients at Kenyatta National Hospital were diagnosed at stage III or IV during 2014 to 2016.[2]However, beyond the referral-network indicators, turnaround targets and laboratory-quality measures, the supplied text does not specify a consolidated national indicator framework, reporting hierarchy, evaluation timetable, surveillance schedule, performance targets or named document-level accountability body.[15][20][27]

Costing & Financing

The guidelines describe significant diagnostic resource requirements and acknowledge the economic burden of cancer, but do not provide a Kenyan implementation budget, programme costing framework, quantified funding gap, financing plan or resource-mobilisation strategy.[5][2][4]

• Recognise that global direct and indirect costs of cancer prevention and treatment were approximately 1.16 trillion US dollars in 2010.[5]
• Acknowledge financial support for guideline development from Roche and the Clinton Health Access Initiative, without stating the value or terms of that support.[3]
• Require laboratories and collection sites to resource commodities, equipment, trained personnel, quality systems, information technology, transport, courier arrangements and communication systems, without assigning monetary values.[14][19][16]
• Link equipment procurement to expected catchment workload, service-delivery level, staff capacity and the availability of materials and supplies; reliable services or supplies may allow some equipment to be omitted.[20]
• Inform patients or guardians about investigation costs, alongside test indications, expected timelines and possible supplementary procedures, as part of consent and requisition processes.[4]
• Address sustainability through contractual arrangements that fairly allocate resources and liabilities, including remuneration for personnel and institutions.[16]
• Consider service fees and the costs, benefits and alternatives of investigations, disease management and referral decisions as ethical practice considerations.[21][9]

Equipment shortages, inadequate laboratory supplies, insufficient trained personnel and unreliable diagnostic services are identified as implementation constraints.[2][4]The supplied text does not specify allocations for formalin distribution, referral transport, laboratory accreditation, workforce development, ancillary testing, information systems or quality assurance.[3][14][16]